Key points from article :
Elastrin, a biotechnology start-up to develop therapeutics that render calcified tissue and organs supple again.
Received seed funding from Kizoo Technology Capital.
“Elastin fibers become damaged, arterial walls weaken, and the body’s physiological response results in aortic wall stiffening, aneurysms, and hypertension,” - Naren Vyavahare, CSO at Elastrin.
Elastrin developed a platform that can restore vascular health by removing pathological calcification.
Albumin nanoparticles loaded with therapeutic agents directly to the tissue site of interest with anti-elastin monoclonal antibody.
“...improve the efficacy of therapeutic payloads as well as reduce side effects,” - Douglas Mulhall, co-founder of Elastrin.
“Our technology can bring the body back to a state before the damage even occurred," - Matthias Breugelmans, CEO of Elastrin.
"Nobody wants to live forever in an old and sick body, but we do want to live long in a healthy one.”
